Not Signed In - NuVasive Announces IDE Approval To Begin NeoDisc(TM) Pivotal Trial
Thu, 29 Jun 2006 06:00 AM EST
... NuVasive, Inc. (Nasdaq:NUVA), a medical device company focused on developing products forminimally disruptive surgical treatments for the spine, announced today ithas received conditional approval of an Investigational Device Exemption(IDE) from the U.S. Food and Drug Administration (FDA) to begin clinicaltrial enrollment of its NeoDisc cervical disc replacement device. [click link for full article] ...
Related Topics
- Clinical Trials
- Tarceva
- Vaccine Testing & Approval
- The signs and symptoms related to the central nervous system may be irreversible if treatment is not begun within 6 months of when these symptoms begin.
- Desipramine
- Trastuzumab
- Eletriptan
- Cardiovascular Health
- Bevacizumab Injection
- Sertraline
- Crohn's Disease
- Pancreatic Cancer
- Child Sexual Abuse
- Patient Issues
- Advocacy
- Ovarian Cancer
email this page
print this page
bookmark this page
feedback on this page
